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The primary cause of Huntington’s disease (HD) is
expression of huntingtin with a polyglutamine expan-
sion. Despite an absence of consensus on the mech-
anism(s) of toxicity, diminishing the synthesis of
mutant huntingtin will abate toxicity if delivered to
the key affected cells. With antisense oligonucleo-
tides (ASOs) that catalyze RNase H-mediated degra-
dation of huntingtin mRNA, we demonstrate that
transient infusion into the cerebrospinal fluid of
symptomatic HD mouse models not only delays
disease progression but mediates a sustained
reversal of disease phenotype that persists longer
than the huntingtin knockdown. Reduction of wild-
type huntingtin, along with mutant huntingtin,
produces the same sustained disease reversal.
Similar ASO infusion into nonhuman primates is
shown to effectively lower huntingtin in many brain
regions targeted by HD pathology. Rather than
requiring continuous treatment, our findings estab-
lish a therapeutic strategy for sustained HD disease
reversal produced by transient ASO-mediated dimi-
nution of huntingtin synthesis.
INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disease caused by a CAG expansion in exon 1 of
the huntingtin gene (Huntington’s Disease Collaborative
Research Group, 1993). This mutation translates into an elon-
gated glutamine tract in the N terminus of the huntingtin protein.
Patients with HD display progressive movement dysfunction,
including hyperkinetic involuntary movements, chorea, and dys-
tonia, as well as cognitive impairments. Presently, there is no
effective treatment for HD. The majority of potential therapies
now under development are aimed at ameliorating symptoms
of one of several proposed molecular consequences of mutanthuntingtin, i.e., at downstream targets in one of the many poten-
tial pathways possibly involved in HD pathogenesis (Melone
et al., 2005).
Irrespective of the many mechanistically divergent proposals
for the underlying toxicity of expanded huntingtin, a therapy
aimed at diminishing the synthesis of the toxic mutant protein
is an approach that will directly target the primary disease mech-
anism(s), as long as it is effective in the key HD-affected cells and
any coincident suppression of wild-type huntingtin is tolerated.
Gene silencing strategies that suppress the synthesis of hunting-
tin that could be deployed as potential therapeutics include
virally encoded short-hairpin RNAs (shRNAs) or microRNAs
(miRNAs) (Franich et al., 2008; Harper et al., 2005; Machida
et al., 2006; McBride et al., 2008; Rodriguez-Lebron et al.,
2005), as well as direct infusion of synthetic siRNAs (DiFiglia
et al., 2007; Wang et al., 2005). In their current forms, each of
these agents needs to be delivered by direct intraparenchymal
injections, and therapeutic correction is limited to only a small
portion of the striatum immediately adjacent to the sites of injec-
tion (Boudreau et al., 2009; DiFiglia et al., 2007; Drouet et al.,
2009; Harper et al., 2005; McBride et al., 2008).
While the striatum is particularly vulnerable to mutant hunting-
tin-mediated toxicity, huntingtin is ubiquitously expressed
(Hoogeveen et al., 1993), and selective expression of mutant
huntingtin in striatal neurons is not sufficient to cause locomotor
deficits or neuropathology in rodents (Gu et al., 2007). To date,
the collective evidence strongly supports a disease mechanism
in which mutant huntingtin expression in multiple cell types
within at least the striatum and cortex is likely required for
disease development and progression. Indeed, cortical thinning
is observed in human patients prior to the onset of symptoms
(Rosas et al., 2002; Rosas et al., 2006), and by endstage, typi-
cally more than 30% of an HD patient’s brain mass is lost
(de la Monte et al., 1988). Finally, the human striatum accounts
for only 1% of the total brain volume, indicating the disease
is affecting other areas of the brain. All of this evidence suggests
that a fully effective treatment of HD will likely require targeting
multiple brain regions.
An alternative approach to preceding efforts for achieving
reduction in huntingtin synthesis is infusion of single strandedNeuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc. 1031
Figure 1. Sustained Reduction in Human and Mouse Huntingtin mRNA and Protein by Transient ASO Infusion into the CNS
(A) Dose response for HuASO in the brain of BACHDmice immediately following continuous 2 week infusion of a human huntingtin targeting ASO (HuASO) at 10,
25, or 50 mg/day. Human huntingtin mRNA levels determined by qPCR and are expressed as mean ± SEM percent (%) of human huntingtin mRNA relative to
saline treated controls (n = 3 per dose).
(B–E) Animals treatedwith 50mg/dayHuASOeuthanized at 0, 4, 8, 12, and16weeksposttreatment termination (n =4per timepoint per dose). (B) Concentrationsof
accumulated HuASO in brain tissue measured by capillary gel electrophoresis. (C) Levels of human mRNAs as measured by qPCR. (D) Soluble mutant huntingtin
levels quantified with time resolved forester resonance energy transfer (TR-FRET) assay. (E) Immunoblot of total huntingtin levels in brains of HuASO infused
mice. The more slowly migrating band is human huntingtin protein (BACHD Tg); the more rapidly migrating band is endogenous mouse huntingtin (Mouse HTT).
(F–H) Animals treatedwith 75 mg/dayMoHuASO euthanized at 0, 2, 4, 6, 8, 11, and 16weeks posttreatment termination (n = 4 per time point per dose). Levels of (F)
human and (G)mouse huntingtin mRNAs asmeasured by qPCR. (H) Immunoblot of total huntingtin levels in brains of infusedmice. Asterisks (*p < 0.05, **p < 0.01,
and ***p < 0.001) denote statistically significant changes relative to saline infused animals (Two-way ANOVA and Bonferroni’s post hoc tests).
See also Figure S1.
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mRNAs and direct their catalytic degradation through the action
of RNase H, an endogenous enzyme present in mostmammalian
cells (Cerritelli and Crouch, 2009; Crooke, 1999). Phosphoro-
thioate-modified chimeric ASOs with 20-O-methoxyethyl (MOE)
anddeoxynucleotide (DNA) sugarmodificationsarewater soluble
and resistant to exonucleases (Bennett and Swayze, 2010; Henry
et al., 2001; Yu et al., 2004), and RNAs paired with them are effi-
ciently degraded by RNase H. We describe here development of
a therapeutic strategy forHDusing transient ASO infusion into the
central nervous system that effectively suppresses huntingtin
accumulation and generates sustained phenotypic reversal in
HD-like disease after transient huntingtin reduction in rodents.
RESULTS
ASOs Facilitate Suppression of Huntingtin
that Is Sustained for Three Months Postinfusion
into the Nervous System
To determine the extent and duration of suppression of mutant
huntingtin synthesis achievable with ASO infusion into the1032 Neuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc.nervous system, a 20-mer phosphorothioate modified oligonu-
cleotide complementary to human huntingtin mRNA (HuASO)
and containing 20-O-(-2-methoxy) ethyl modifications on the
five nucleotides on the 30 and 50 ends to increase its stability,
tolerability and potency (Bennett and Swayze, 2010; Henry
et al., 2001; Yu et al., 2004) was infused continuously (10, 25,
or 50 mg/day) for 2 weeks into the right lateral ventricle of the
BACHD mouse model of HD. BACHD mice harbor a full-length
mutant human huntingtin gene with an expansion of 97 CAG/
CAA repeats and express the mutant protein at approximately
1.5 times the level of the endogenous mouse huntingtin (Gray
et al., 2008).
Infusion of the HuASO significantly decreased the levels of
humanhuntingtinmRNA in adose-dependentmanner (Figure 1A)
(25 mg/day, to 42% of the level of vehicle alone [p = 0.007];
50 mg/day, to 28%vehicle [p = 0.005]). For all subsequent studies
a dose of 50 mg/day of HuASO was used. At the end of infusion,
the ASO had accumulated to significant levels (170 ± 16 mg/g
brain tissue) that then decreased in abundance with approxi-
mately first order kinetics over a subsequent 16 week period
(Figure 1B). This pharmacokinetic profile is similar to that
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of similarly modified ASOs (Yu et al., 2001). At all times postinfu-
sion, more than 90% of the remaining ASO was full length, as
judged by capillary gel electrophoresis, indicating the ASO was
chemically stable within cells of the nervous system.
A significant reduction in human huntingtin mRNA levels
(reduced to 38%± 3% [p < 0.001] of the vehicle-infused animals)
was observed at the earliest time point (after 2 weeks of contin-
uous infusion). This reduction persisted for 12 weeks, rising back
to untreated levels only 16 weeks after the termination of treat-
ment (Figure 1C). At 12 weeks posttreatment, only 13 mg/g of
ASO was present in the brain (Figure 1B), yet huntingtin reduc-
tion persisted, indicating that low doses of ASO in the correct
cellular compartments are sufficient to be effective and aremain-
tained with long in vivo half lives, particularly in the brain where
many of the cells are nondividing. A similar pattern of reduction
was observed for the accumulated mutant human huntingtin
protein; however, the reduction was delayed relative to the
mRNA (Figure 1D), reflecting a longer half-life of the protein
than the mRNA. Nevertheless, by 4 weeks posttermination of
ASO infusion, mutant human huntingtin protein levels were
reduced by two-thirds and gradually returned to untreated levels
16 weeks after the end of infusion (Figure 1D). As expected,
mouse huntingtin protein (Figure 1E) andmRNA (see Figure S1A,
available online) levels remained unaltered at all time points, as
expected from the 8 base difference in complementarity of the
mRNA with the HuASO.
The durable suppression achieved with the human huntingtin
selective ASO (HuASO) was replicated with a second ASO
complementary to a sequence that is identical in mouse and
human huntingtin (MoHuASO). A 75 mg/day 2 week infusion of
MoHuASO into the right lateral ventricle of BACHD animals
significantly reduced both human (Figure 1F) and mouse (Fig-
ure 1G) huntingtin mRNA (human reduced to 31% ± 4% [p <
0.001] and mouse reduced to 17% ± 4% [p < 0.001] of the
vehicle-infused animals). Mouse and human huntingtin mRNA
and protein remained suppressed for 3 months and did not
return to vehicle treated levels until 16 weeks after the end of
treatment. Accumulated protein levels were similarly reduced
beginning 2 weeks after the reduction in RNA, and remaining
suppressed until 16 weeks posttreatment termination (Fig-
ure 1H). As expected, control ASOs (Cnt1 and Cnt2), without
complementarity in the mouse genome or human huntingtin,
did not suppress mouse or human huntingtin mRNA (Figures
S1B and S1C).
To determine the distribution and cellular uptake of antisense
oligonucleotides (ASOs) delivered by infusion into the CNS,
an antibody that selectively recognizes the phosphorthioate
backbone of the ASOs (see Figure S2A for additional saline
controls from the various brain regions) was used to probe
30 mm coronal sections from the olfactory bulb to the cerebellum
(see Figure S2B for schematic of sectioning and dissections).
Following a two week infusion of the HuASO into nontransgenic
animals, ASO accumulation was detected in the neurons of most
brain regions, including the frontal cortex, striatum, thalamus,
midbrain, brainstem, and cerebellum, with the exception of
dense regions of white matter and cerebellar granule cells
(Figure 2A). ASOs were also present in neuronal nuclei, cellbodies and neurites, as determined by colocalization of accumu-
lated ASOs with the neuronal marker NeuN (Figure 2B). ASOs
also accumulated in nonneuronal cells, including glial fibrillary
acidic protein (GFAP)-expressing astrocytes (Figure 2B).
In BACHD mice, the HuASO significantly suppressed produc-
tion of human huntingtin mRNA in the cortex and striatum both
ipsilateral (cortex to 28% ± 6% and striatum to 19% ± 4% of
vehicle [p < 0.001]) and contralateral to the injection site (cortex
to 36% ± 4% and striatum to 39% ± 6% of vehicle [p < 0.001])
(Figures 2C and 2D), as well more caudal regions including the
thalamus (to 25% ± 5% of vehicle [p < 0.001]), midbrain (to
53% ± 7% of vehicle [p = 0.0096]), and brainstem (to 54% ±
3% of vehicle [p < 0.001]) (Figure 2E).
Suppression of Mutant Huntingtin Synthesis Reverses
Disease Course in YAC128 Mice
To determine if suppression of mutant huntingtin, by ASO infu-
sion into the CNS, could affect HD-like disease development,
we initially used YAC128 mice that express a full-length mutant
human huntingtin transgene (including the human huntingtin
promoter) to about 75% the level of normal mouse huntingtin.
These mice develop a progressive phenotype with many of the
hallmarks of human HD, including motor and cognitive dysfunc-
tion, as well as brain atrophy (Hodgson et al., 1999). The HuASO,
complementary to human huntingtin mRNA, was infused for
2 weeks into the right lateral ventricle of YAC128 mice beginning
at 3 months of age, after which the osmotic pumps used to
deliver the ASOs were removed and the animals were allowed
to recover for 2 weeks prior to being assessed for motor coordi-
nation and anxiety (Figure 3A). As in BACHDmice, treatment with
the human huntingtin specific ASO (HuASO) led to a significant
reduction in huntingtin mRNA (p = 0.0012) and protein levels
(to 16% ± 3% of vehicle [p < 0.001]) at 6 weeks after the termina-
tion of treatment (Figure 3C).
Motor deficits, which develop in the YAC128 animals as early
as 2 months of age, improved within 1 month of initiating HuASO
treatment (4 months of age), and were significantly different from
saline (p = 0.024) and restored to nontransgenic control levels
after two months (5 months of age) (Figure 3B). Behavioral
assays directed at measuring anxiety (elevated plus maze; Fig-
ure S3A) and ambient motor activity (open-field; Figure S3B)
revealed that deficits in ASO-treated mice were restored to non-
transgenic performance levels within 2 months of ASO infusion,
although improvements in these two behaviors failed to reach
significance. Thus, transient ASO-mediated treatment after
disease initiation leads to a sustained reduction in expanded
huntingtin accumulation that in turn is reflected in a progressive
restoration of initial motor deficits to normal over a 2 month
period.
To test for a therapeutic benefit from reducing expanded
huntingtin in older animals, the HuASO was infused for 2 weeks
into 6-month-old (Figure 3D), more phenotypic YAC128 mice.
This yielded a sustained reduction in mutant huntingtin mRNA
and protein (which remained suppressed to 42% [p < 0.001]
and 44% [p = 0.0057], respectively) when measured 2.5 months
after discontinuing treatment (Figure 3E). Phenotypic reversal
was again achieved. After a 2 month lag, motor function
improved and treated animals were no longer significantlyNeuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc. 1033
Figure 2. ASOs Infused into the Cerebrospinal Fluid Distribute and Are Active throughout the CNS
(A and B) An ASO targeting human huntingtin (HuASO) was infused continuously for 2 weeks into the right lateral ventricle of 2-month-old nontransgenic mice.
Immunohistochemical staining of antisense oligonucleotides (red), neurons (NeuN, green), astrocytes (GFAP, green), and nuclei (DAPI, blue). Antisense oligo-
nucleotides are present in most neuronal nuclei (B, top inset), astrocytes (B, bottom inset) and other nonneuronal cells (examples denoted with *). Scale bar:
(A) 100 mm, (B) 50 mm and inset 5 mm. Representative example from two independent experiments, n = 4 per treatment.
(C–E) HuASO was infused continuously for 2 weeks into the right lateral ventricle of 2-month-old BACHD mice. Immunoblot of human (upper band) and mouse
(lower band) huntingtin, and quantification of human huntingtin mRNA levels (mean % ± SEM relative to saline controls) 8 weeks posttreatment termination in
BACHD (C) cortex ipsilateral and contralateral to the injection site, (D) ipsilateral and contralateral striatum (E) thalamus, midbrain, brainstem, and cerebellum.
Asterisks (*p < 0.05, **p < 0.01, and ***p < 0.001) mark statistically significant changes relative to saline infused animals (n = 5 per treatment, two-tailed unpaired
t tests).
See also Figure S2.
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ioral characteristics improved sufficiently to reach nearly
normal levels by 9 months of age (Figures S3C and S3D), albeit
these did not reach a p < 0.05 level of confidence. Thus, while
mice transiently treated at this older age (6 months) never
reached the improvement achieved in younger animals, therapy
initiated in these more phenotypic mice provided sustained
suppression of mutant huntingtin synthesis and partial reversal
of disease characteristics 3 months after stopping treatment
(Figures 3A–3C).
Long-Term Sustained Reversal of Disease in BACHD
Mice after Transient ASO-Mediated Suppression
of Huntingtin Synthesis
Efficacy of huntingtin ASO-mediated disease attenuation was
tested in a second mouse model, the BACHD animals which,
like the YAC128 animals, recapitulate characteristics of human1034 Neuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc.HD from expression of the full-length expanded human hunting-
tin gene under the control of the endogenous huntingtin
promoter. BACHD mice develop progressive motor incoordina-
tion, hypokinetic motor activity, and brain atrophy. Six-month-
old BACHD mice were infused for 2 weeks with an ASO specific
to human huntingtin (HuASO at 50 mg/day) or vehicle and then
followed for 6 months (Figure 4A), 3 months longer than the
YAC128 mice were followed (Figures 3D–3F, S3C, and S3D).
The degree of human huntingtin mRNA suppression (to 25% of
vehicle) was the same in aged 8-month-old BACHD mice (Fig-
ure 4B) as it was in younger BACHD animals (Figure 2C).
BACHD mice develop significant symptoms by 6 months of
age (Figure 4C; with a latency to fall in a rotarod task of 94 ± 6 s
versus 197 ± 12 in normal, nontransgenic animals). Eight weeks
after the initiation of treatment, the motor skills of the HuASO-
treated BACHD mice were improved compared to their initial
performance before treatment (one-way repeated-measures
Figure 3. Motor Coordination Reverts to
Normal Levels after Suppression of Mutant
Huntingtin with ASO Therapy
(A) Schematic of experimental design (B and C). At
3 months of age YAC128 mice were infused into
the right lateral ventricle with an ASO that targets
human huntingtin (HuASO) or saline for 2 weeks at
50 mg/day.
(B) Motor performance on a rotarod of mouse
cohorts before (3 months old) and 1 and 2 months
after ASO infusion (4 and 5months of age) (mean ±
SEM; n = 7–16).
(C) Human huntingtin protein levels in brains of
YAC128 mice 6 weeks after treatment termination.
Data are expressed as mean percentage ± SEM
relative to saline treated controls (All animals in B
were analyzed, two-tailed unpaired t test).
(D) Schematic of experimental design (E and F).
Six-month-old YAC128 mice were intraventricu-
larly infused for 2 weeks with 50 mg/day of HuASO
or a vehicle control (saline).
(E) Human huntingtin protein levels in brains of
YAC128 mice sacrifice at 9 months of age,
3 months after treatment. Data are expressed as
mean percentage ± SEM relative to saline treated
controls (all animals in F were analyzed, two-tailed
unpaired t test).
(F) Motor performance on a rotarod of mouse
cohorts at ages between 6 and 9 months (mean ±
SEM; n = 8–12). Asterisks denote (*p < 0.05, **p <
0.01, and ***p < 0.001) statistically significant
differences of YAC128 HuASO treated mice (using
one-way ANOVA and Tukey’s post hoc test for all
behavioral tests).
See also Figure S3.
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to 8 month old BACHD HuASO, p = 0.0002) and to their BACHD
littermates treated with control ASOs (CntASO) (Figure 4C). This
improvement in performance persisted through 12 months of
age (the oldest age assessed), a time 6 months after treatment
had ended and more than 2 months after restoration of mutant
huntingtin synthesis to untreated levels (Figures 1C and 1E).
Similarly, a sustained, phenotypic reversal in behavior was
seen in an open-field assay (Figure 4D). This latter phenotypic
improvement inASO-treated animalswasnot seenuntil 6months
after initiating ASO infusion, during which time the saline treated
BACHD animals had become progressively more hypoactive.
Reversal of motor phenotype was likely due to suppression
of mutant huntingtin, as ASOs that do not target huntingtin
(CntASOs) did not improve motor coordination (Figure 4C) or
hypoactivity (Figure 4D). Amelioration of motor phenotype
was not the result of a change in body mass, as transient
suppression of mutant huntingtin levels did not ameliorate trans-
gene-mediated gain in body weight (Van Raamsdonk et al.,
2006; Figure S4A). Treatment with the HuASO also did not alter
brain mass in BACHD mice (Figure S4B), consistent with
improvement of function arising from recovery of damaged
neurons, rather than prevention of degeneration.
To verify the longevity of the beneficial effect, a second cohort
of BACHD animals was treated for 2 weeks at 6 months of age
with the human huntingtin ASO (HuASO) or vehicle, and behaviorwas assessed at 12 and 15 months of age (Figure 4E). Immedi-
ately following behavior assessment at 15 months of age,
huntingtin levels were determined. Hypoactivity was improved
in ASO-treated BACHD animals at 6 (p = 0.019) and 9 (p =
0.047) months posttreatment (12 and 15 months of age, respec-
tively) (Figure 4F). Motor coordination (rotarod) was similarly
improved 9 months after treatment with the human huntingtin
ASO (p = 0.05) (Figure 4G). At 15 months of age, BACHD animals
are anxious, as measured by failure to explore a lit arena (light/
dark choice, time in light 88 ± 27 s for saline treated BACHD
and 248 ± 20 s for nontransgenic animals, p = 0.036). Anxiety
was significantly ameliorated in HuASO treated BACHD animals
(compared to saline treated BACHD, p = 0.027) and was similar
to nontransgenic levels (Figure 4H).
Nine months after treatment, human huntingtin levels in ASO-
treated animals, measured immediately after the improvement in
motor activity, anxiety, and motor coordination was recorded,
were comparable to vehicle levels (Figures 4I and 4J). Thus,
the improvement in behavior at 15 months came after mutant
huntingtin had been restored to its initial level, demonstrating
that the beneficial effects of ASO treatment persist for longer
than target suppression.
Using an antibody directed against the expanded polyglut-
amine tract of mutant huntingtin (3B5H10 whose immunogen
was a human huntingtin fragment containing 65 glutamines)
(Brooks et al., 2004; Peters-Libeu et al., 2012), a diffuseNeuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc. 1035
Figure 4. Sustained Phenotypic Reversal fromTransient ASO Infusion into the CNSof BACHDMice for 8months after Treatment Termination
(A) Schematic of treatment paradigms (B–D). At 6 months of age, BACHD mice were infused for 2 weeks with 50 mg/day of an ASO that targets human
huntingtin (HuASO), ASOs that have no target in the mouse genome (CntASO) or vehicle (Saline). Nontransgenic littermates were infused with vehicle
(Saline).
(B) Levels of human huntingtin mRNAs 2 months posttreatment, as measured by qPCR in BACHD mice treated at 6 months of age (n = 5 per treatment, data are
expressed as mean % ± SEM, two-tailed unpaired t test, p < 0.0001).
(C) Motor performance on a rotarod between ages 6 and 12months, andmeasured every 4 weeks. Asterisks denote statistically significant changes compared to
BACHD HuASO treated animals (mean ± SEM; n = 8–13).
(D) Open-field performance 2 (8 months old, p = 0.111), 4 (10 months old, p = 0.027), and 6 (12 months old, p = 0.034) months posttreatment in BACHD mice
and nontransgenic littermates (mean ± SEM; nontransgenic, n = 3–6; BACHD, n = 12–16).
(E) Schematic of treatment paradigm (F-K). At 6 months of age, BACHD mice were infused for 2 weeks with 50 mg/day of HuASO (red) or saline (black). Non-
transgenic mice are included as behavioral controls (white).
(F) Performance of mice 6 and 9 months after ASO infusion determined by time mobile in an open-field test, p = 0.002 and p = 0.016, respectively (n = 6–8).
(G) Rotarod performance after two consecutive days of training at 9 months posttreatment (15 months of age), p < 0.0001 (n = 6–8).
(H) Light/dark choice at 15 months of age, p = 0.016 (mean ± SEM; n = 6–8). In all instances (F–H), saline treated BACHDmice performed significantly worse than
nontransgenic and HuASO treated BACHD mice (one-way ANOVAs and Tukey’s post hoc tests).
(I) Immunoblot of huntingtin protein 2 and 9 months posttreatment, GAPDH is used as a loading control.
(J) Nine months posttreatment qPCR was used to quantify mouse and human huntingin mRNA levels. qPCR are expressed as mean ± SEM percent (%) of
huntingtin mRNA relative to saline treated controls (n = 6 per treatment).
(K) Immunohistochemical (IHC) staining for mutant huntingtin aggregates with anti-polyglutamine antibody (3B5H10) (brown) and nuclear counterstain hema-
toxylin (blue), 9 months posttreatment. Scale bar: 50 mm. Representative images, n = 6 BACHD per treatment.
See also Figure S4.
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most striatal cells (including medium spiny neurons) of 15-
month-old BACHD mice treated with saline at 6 months of age
(Figure 4K, bottom). In contrast, striatum from 15-month-old
BACHD, treated at 6monthswithHuASO, exhibited only a diffuse
staining pattern, similar to that seen in vehicle treated BACHD
brains, but contained very few aggregates (Figure 4K, middle).
No aggregates or diffused staining were observed in nontrans-
genic brains (Figure 4K, top). Thus, despite the restoration of
soluble mutant protein levels 9 months posttreatment (Fig-
ure 4J), transient suppression of mutant huntingtin was sufficient
to delay the formation of polyglutamine aggregates, and the
delay lasted longer than the reduction of the soluble mutant
protein.
Suppression of Mutant Huntingtin Reverses Disease
Independent of Wild-Type Huntingtin Level
To determine if suppression of endogenous, wild-type huntingtin
attenuates the benefits of lowering mutant huntingtin and to
determine if normal huntingtin can safely be lowered in adult
animals, BACHD and nontransgenic littermates were treated at
2 months of age (Figure 5A) with vehicle, the mutant human hun-
tingtin selective ASO that does not alter normal mouse huntingtin
(HuASO) (Figure S1A) or an ASO that reduces mutant huntingtin
to the same level as the HuASO while simultaneously lowering
normal mouse huntingtin to 75% normal levels (MoHuASO)
(Figures 1F–1H). At treatment, 2-month-old BACHD animals
already exhibit impaired motor coordination (before treatment
the latency to fall of saline treated BACHD mice is 142 ± 11 s
and nontransgenic animals is 197 ± 10 s, p = 0.013) (Figure 5B,
top; see also Figure S5 for all p values).
Selective suppression of mutant huntingtin (HuASO) improved
motor coordination 3 months after treatment (5 months of age;
p = 0.016) and this remained significantly improved compared
to saline treated animals for 5 additional months (p = 0.04;
Figure 5B, top). Remarkably, simultaneous suppression of
mouse (normal) and human (mutant) huntingtin (MoHuASO)
improved motor coordination to a similar magnitude and dura-
tion as selective suppression of mutant huntingtin (HuASO) (Fig-
ure 5B, middle). Hypoactivity was also returned to normal levels
in BACHD animals treated with the human and mouse hunting-
tin-targeting ASO (MoHuASO) and had a similar effect as the
human selective ASO (HuASO) (Figure 5C). Thus, transient
cosuppression of normal huntingtin does not attenuate the
long-term beneficial effect of ASO-mediated mutant huntingtin
suppression.
Treatment of nontransgenic animals with the human huntingtin
targeting ASO (HuASO), which does not target any sequence in
a normal mouse, did not affect performance, consistent with the
beneficial effect in BACHD animals being a direct consequence
of lowered mutant huntingtin (Figure 5B, bottom). Moreover,
a 75% reduction in mouse huntingtin in the normal (nontrans-
genic) adult brain for up to 4 months (by infusion of an ASO tar-
geting both human andmouse RNAs (MoHuASO) (Figure 1G) did
not alter motor coordination (Figure 5B, bottom) or activity (Fig-
ure 5D), indicating that this level of ASO-directed suppression of
normal huntingtin is within a window for therapeutic benefit that
is well tolerated. As expected, 11 months posttreatment, normalandmutant huntingtin levels in these animals was comparable to
vehicle treated controls (Figures 5E and 5F).
ASO Therapy Prevents Brain Loss and Promotes
Survival in an Acute, Fatal Model of HD
To assess the efficacy of ASO treatment in an HD mouse model
that develops a very rapidly progressing fatal disease, we utilized
R6/2 mice that express a fragment of the human huntingtin gene
with an expanded CAG repeat and exhibit a progressive motor
phenotype, a dramatic loss of brain mass, and a lifespan of
approximately 16 weeks (Mangiarini et al., 1996). Infusion of an
ASO designed to target the mutant R6/2 transgene (HuASOEx1)
into the right lateral ventricle of R6/2 animals (50 mg/day for
4 weeks; Figure 6A) selectively suppressed production of human
huntingtin mRNA (by 43% ± 5% compared to vehicle treated
littermates [p = 0.002]; Figure 6B). At treatment initiation (8 weeks
old), R6/2 mice had already developed obvious symptoms and
had sustained gross loss of brain mass (Figure 6C; R6/2
untreated baseline). This loss in brain mass was continuous
with an additional 10% of initial total brain mass lost by week
12 (Figure 6C; R6/2 vehicle treated) and further loss continuing
until endstage.
HuASOEx1 infusion at 8 weeks of age blocked further brain
loss. Brain mass of 12-week-old HuASOEx1 treated animals
(394 ± 14 mg) was comparable to the brain mass of 8-week-
old untreated animals (402 ± 14 mg) and was significantly larger
than the 12-week-old animals that received vehicle (364 ± 10mg
[p = 0.004]; Figure 6C). The retention in brain mass could not
be attributed to ASO-induced inflammation, as infusion of
HuASOEx1 attenuated the presence of astrocytosis and micro-
gliosis in R6/2 brains, as determined by immunohistochemical
staining for glial fibrillary acidic protein (GFAP) and ionized
calcium binding adaptor molecule 1 (Iba1) (Figures S6A–S6C).
Indeed, the volumes of both the right (ipsilateral to the infusion
site) and left (contralateral) sides of the striatum and cortex
trended toward larger in HuASOEx1 human huntingtin ASO
treated mice than in vehicle-treated and control ASO- treated
animals (Figures 6D–6F).
ASO-mediated suppression of mutant huntingtin mRNA initi-
ated mid-disease (8 weeks) also significantly increased lifespan
of R6/2 mice (to a median of 136 days) compared with vehicle-
treated littermates (median survival of 113 days [p = 0.0498]; Fig-
ure 6G). Despite the prevention of brain loss and improvement in
survival and suppression of new huntingtin synthesis, mutant
huntingtin aggregates were not substantially altered in the time
course of this experiment (Figure 6H). Thus, once formed the
large mutant huntingtin-containing aggregates are cleared very
slowly. More importantly, disease mechanism underlying mutant
huntingtin-derived brain loss and disease progression must be
independent of these mutant protein aggregates in this very
aggressive disease model.
Suppression of Huntingtin Levels in the CNS after ASO
Infusion into Nonhuman Primates
Todetermine the effectiveness of ASOdelivery into a larger,more
complex brain whose anatomy more closely resembles the
human brain, we used continuous infusion into the cerebrospinal
fluid ofRhesusmonkeys (brain size 90g, 75cm3, that is, 180 timesNeuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc. 1037
Figure 5. Simultaneous Suppression of Mutant and Normal Huntingtin Does Not Attenuate Sustained Phenotypic Reversal
(A) Schematic of experimental design. At 2 months of age, BACHDmice and nontransgenic littermates (NonTg) were infused for 2 weeks with 50 mg/day HuASO
(red), 75 mg/day of an ASO that targets mouse and human huntingtin (MoHuASO) (blue) or saline (black) (B–D, nontransgenic, n = 11–15; BACHD, n = 15–20).
(B) Motor coordination (rotarod) immediately before treatment (2 months old) and monthly for 11 months after treatment. (Top) HuASO treated BACHD animals,
saline treated BACHD animals and saline treated nontransgenic littermates, asterisks denote significance relative to HuASO treated BACHD animals. (Middle)
MoHu treated BACHD animals and HuASO treated BACHD animals, no significant differences were found. (Bottom) Nontransgenic animals treated with saline,
HuASO or MoHuASO, no significant differences were found.
(C and D) Time mobile in the open-field 3 months posttreatment in 5-month-old (C) BACHD (p = 0.025) and (D) nontransgenic littermates (p = 0.515).
(E) Immunoblot of huntingtin from (top) BACHD mice and (bottom) nontransgenic littermates, 1 month or 11 months posttreatment.
(F) Eleven months posttreatment qPCR was used to quantify mouse and human huntingin mRNA levels. qPCR are expressed as mean ± SEM percent (%) of
huntingtin mRNA relative to saline controls (BACHD, ASO n = 4 and saline n = 3; nontransgenic, ASO n = 3 and saline n = 2). Asterisks (*p < 0.5, **p < 0.01, ***p <
0.001) denote statistically significant differences (using one-way ANOVA and Tukey’s post hoc test for all assays). All behavior data expressed as mean ± SEM.
See also Figure S5.
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Transient ASO Therapy Produces Reversal of HDlarger than the mouse brain and about 1/15th the volume of
a human brain). Intrathecal infusion was chosen as several
devices have already been approved for infusion of drugs by
this route of administration into humanpatients, and another anti-
sense drug is currently in clinical trials for the treatment of familial
ALS (Smith et al., 2006). Moreover, it is considerably safer to
surgically implant and chronically maintain a catheter in the intra-
thecal space than in the lateral ventricle or the brain parenchyma.1038 Neuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc.An ASO completely complementary to both Rhesus monkey
and human huntingtin mRNA (MkHuASO) was infused into the
cerebrospinal fluid of Rhesus monkeys at a dose of 4 mg/day
for 21 days. Analysis of a series of rostral to caudal sections
was used to determine that ASOs were distributed to neurons
of most periventricular and lateral brain regions, as determined
by immunohistochemistry with an antibody (anti-pan ASO) that
recognizes the backbone of the phosphorothioate containing
Figure 6. Delayed Disease Progression and Prolonged Survival in R6/2 Mice after CNS Infusion of an ASO to Mutant Human Huntingtin
(A) Schematic of treatment paradigm. R6/2 mice and nontransgenic littermates (NonTg) received intraventricular infusion of 50 mg/day of human huntingtin ASO
targeting the R6/2 transgene (HuASOEx1), a control ASO (Cnt1ASO) or saline. Treatment began at 8 weeks of age and animals were euthanized at 12 weeks of age
for RNA analysis, pathology, or aged for survival.
(B) Human huntingtin mRNA levels in brain of R6/2 mice treated with ASO targeting human huntingtin compared to saline treated mice (n = 4). qPCR data ex-
pressed as mean ± SEM; percent (%) of RNA is relative to saline treated controls (two-tailed unpaired t test, **p < 0.01).
(C) Total brain weight (mg) immediately following the 4-week ASO infusion. Untreated 8-week-old R6/2 mice are included for comparison of the disease state at
the time of treatment initiation (HuASOEx1 treated R6/2, n = 10; saline treated R6/2, n = 11; control ASO treated R6/2, n = 8; saline treated Nontg, n = 10; HuASOEx1
treated Nontg, n = 5; and untreated 8-week-old R6/2, n = 4, p < 0.0001). Asterisks (**p < 0.01) denote statistically significant differences using one-way ANOVA,
Tukey’s post hoc test. Data expressed as mean ± SEM.
(D) Representative image of HuASOEx1 treated R6/2 brain (left) or saline treated R6/2 brain (right) stainedwith cresyl violet. The striatum is outlined (red: HuASOEx1
treated, black: saline treated).
(E and F) Quantification of (E) striatal and (F) cortical volume in R6/2 both ipsilateral and contralateral to injection site using the cavaleri method (saline, n = 9;
HuASOEx1, n = 10; CntASO, n = 7).
(G) Plots of ages of R6/2 mice at time of death (saline, n = 7; HuASOEx1, n = 9). Data are expressed as Kaplan-Meyer survival curves (p = 0.049).
See also Figure S6.
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Transient ASO Therapy Produces Reversal of HDASO (see Figure S7 for saline controls). ASOs accumulated in
most regions of the cortex (Figures 7A and S7), distributing to
pyramidal neurons as well as the surrounding tissue (Figure 7A,
bottom right). Immediately after infusion, huntingtin mRNA
levels in the anterior (frontal) and posterior (occipital) cortex of
ASO-infused animals were significantly reduced to 47% (p =
0.005) and 63% (p = 0.015) of the normal levels, respectively
(Figure 7F).
The infused MkHuASO could also be detected in the caudate
nucleus of the striatum (Figure 7A, bottom left), particularly in
periventricular medium spiny neurons, and levels of huntingtinmRNA trended toward a 25% reduction (p = 0.23) (Figure 7F).
ASOs were also distributed to neurons in the hippocampus (Fig-
ure 7B), pons (Figure 7C), cerebellum (Figure 7D), and spinal
cord (Figure 7E). Huntingtin mRNA levels remained reduced in
the anterior (frontal) cortex (to 53%), posterior (occipital) cortex
(to 68%) and spinal cord (to 46%), for 4 weeks after the termina-
tion of treatment, and only began to rise toward normal levels
8 weeks after the termination of treatment (Figure 7G), similar
to the duration of target-reduction observed in the rodent brain
(Figure 1C). Thus, ASOs infused transiently into the cerebro-
spinal fluid of nonhuman primates produced sustained reductionNeuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc. 1039
Figure 7. Broad ASO Distribution and Suppression of Huntingtin mRNA in a Nonhuman Primate Brain after ASO Infusion into the
Cerebrospinal Fluid
(A) Distribution of ASOs in the Rhesus monkey brain visualized with immunostaining (anti-pan ASO) and counterstained for nuclei with hematoxylin following
a 21 day intrathecal infusion of 4mg/day ASO targetingmonkey huntingtin (MkHuASO), including (A, bottom right) pyramidal neurons of the cortex and (A, bottom
left) medium spiny neurons in the caudate.
(B) ASO distribution in the hippocampus and (B, bottom right) neurons in the dentate gyrus.
(C) ASO accumulation in a coronal section including the pons and cerebral aqueduct, CA; ASO is present in pontine cell bodies despite low levels of ASO
accumulation in the surrounding tissue (lower panel).
(D) ASO accumulation in the cerebellum and surrounding brain regions.
(E) ASO accumulation in motor neurons in the spinal cord.
(F) mRNA levels of monkey huntingtin from various brain regions immediately following infusion, as determined by qPCR (n = 3 per treatment, two-tailed unpaired
t tests).
(G) Monkey huntingtin mRNA levels in the anterior (frontal) cortex (red), posterior (occipital) cortex (orange), and cervical spinal cord (yellow), 0, 2, 4, and 8 weeks
posttreatment termination (n = 3 per treatment, two-way ANOVA, Bonferroni post hoc test). Data expressed as mean ± SEM, percent (%) of RNA relative to
vehicle treated controls (blue). Asterisk (*p < 0.5, **p < 0.01, ***p < 0.001) denotes statistically significant differences.
See also Figure S7.
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including those heavily implicated in HD pathology.
DISCUSSION
Our efforts have established what we believe is now a clinically
feasible, dose dependent approach for providing long-term
disease mitigation and partial phenotypic reversal of Hunting-
ton’s disease, as well as establishing the utility of sustained
benefit from a transient reduction of mutant huntingtin synthesis
and accumulation. We have obtained significantly suppressed
production of huntingtin mRNA and protein in a regulatable,1040 Neuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc.dose-dependent manner throughout most regions of the
nervous system of rodents and nonhuman primates by exploiting
the natural flow of cerebrospinal fluid to widely deliver ASOs
after focal infusion. When used in each of three mouse models
of HD, short term therapy with ASOs produced sustained pheno-
typic disease reversal or extended survival while stopping loss of
brain mass. ASO suppression of huntingtin mRNA levels was
surprisingly long lived (2 or 3 months) in mice and nonhuman
primates. Most surprisingly, and of high impact for therapy
design, partial disease reversal after transient therapy was
demonstrated to persist for at least 4 months after mutant
huntingtin RNA and protein levels had returned to their initial
Neuron
Transient ASO Therapy Produces Reversal of HDlevels and was unaffected by simultaneous reduction of normal
huntingtin.
Our results extend, with a clinically viable strategy, earlier
efforts demonstrating delayed development of motor impair-
ments in transgenic mouse models of HD using either intraven-
tricularly delivered siRNAs (delivered at birth) (Wang et al.,
2005) or focal viral delivery of shRNAs presymptomatically into
the striatum (Denovan-Wright et al., 2008; Harper et al., 2005;
Rodriguez-Lebron et al., 2005). Other efforts with siRNA (DiFiglia
et al., 2007) and virally delivered shRNAs (Drouet et al., 2009;
Franich et al., 2008) injected into the striatum with focal expres-
sion of mutant huntingtin (also injected into the striatum, and
encoded by virus) have prevented motor impairments, striatal
atrophy, and cell loss. To this, our efforts have established
slowed disease progression, extension of survival and sustained
phenotypic reversal from transient ASO infusion into symptom-
atic adult animals.
Furthermore, in contrast to prior approaches, we have estab-
lished that the ASO infusion approach is effective and achieves
a broad distribution in the nonhuman primate brain. This bodes
well for use of an ASO approach in human therapy. It is well
established that huntingtin is not simply a disease of the striatum
(Gu et al., 2007). Atrophy in cortical regions is linked to patients
with phenotypes manifesting primarily as emotional and
cognitive impairment (Rosas et al., 2008), suggesting that a
treatment selectively targeting the striatum is not likely to amelio-
rate these symptoms. However, a treatment with a technology
like ASOs capable of targeting many regions of the brain has
the potential to treat more of the symptoms of this complex
disease.
Phenotypic reversal after a therapeutically feasible, transient
ASO infusion initiated after symptom onset in an adult animal
is consistent with phenotypic reversal in a conditional mouse
model (after doxycycline administration to suppress transcrip-
tion of mutant huntingtin driven by a tet-promoted transgene;
Yamamoto et al., 2000). Remarkably, the time scales for
phenotype reversal are virtually identical among the two
mouse models presented here (YAC128 and BACHD) and the
previously characterized conditional model (Dı´az-Herna´ndez
et al., 2005). In all cases, suppression of mutant huntingtin for
8 weeks is required before reversal in phenotype is apparent.
This suggests that, at least in the rodent brain, mutant huntingtin
mediated dysfunction, regardless of whether it is caused by
expression of an expanded full-length transgene or a fragment,
shares similar mechanism and timing. More importantly, our
evidence establishes that a considerable proportion of the
confirmed phenotype reflects reversible dysfunction, even in
aged animals. Moreover, by comparing therapeutic intervention
inmultiplemodels at various disease stages, it is clear that earlier
treatment produces a quicker and more robust reversal of
disease.
Regarding mechanism of mutant huntingtin toxicity, the reten-
tion of brain mass following suppression of mutant huntingtin
synthesis in the R6/2mousewithout reduction inmutant hunting-
tin aggregates indicates that those aggregates are not the
primary toxic species responsible for the remarkable loss in brain
mass in this aggressive model. Conversely, a delay in aggregate
formation in the ASO-treated BACHD mice is consistent withhuntingtin suppression allowing clearance of toxic oligomers
that seed the large aggregates or toxicity derived from the large
aggregates.
A key previously unresolved question of relevance for all gene
silencing approaches is how essential is normal huntingtin
encoded by the unmutated allele in the adult nervous system.
Huntingtin is essential for one or more early developmental steps
(Nasir et al., 1995; White et al., 1997; Zeitlin et al., 1995). A
continued need for huntingtin in the CNS has been proposed
from efforts in mouse models with deletion of both huntingtin
alleles at embryonic day 15.5 or postnatal day 5 (Dragatsis
et al., 2000) and in cultured neuronal cells (Gauthier et al.,
2004; Zuccato et al., 2003). However, no evidence has demon-
strated toxicity following suppression of huntingtin in the adult
brain. In fact, simultaneous suppression of mutant and normal
huntingtin by 60% in the adult rodent striatum, and suppression
of normal huntingtin by 45% in the nonhuman primate striatum
were both well tolerated (Boudreau et al., 2009; Drouet et al.,
2009; McBride et al., 2011).
Our ASO approach has extended these earlier efforts:
reducing huntingtin levels by 75% throughout the CNS neither
exacerbates disease nor lessens the therapeutic benefit from
suppression of mutant huntingtin. Moreover, suppression of
normal huntingtin for up to 3 months (the latest time assessed)
in healthy primates was well tolerated. These findings provide
experimental support for the existence of a therapeutic window
for safe, yet efficacious, transient suppression with a nonallele
selective ASO approach. They also lay the foundation for sus-
tained phenotypic reversal from allele selective reduction of
mutant huntingtin with mutant CAG targeting ASOs (Gagnon
et al., 2010; Hu et al., 2009) or ASOs that target single nucleotide
polymorphisms present in the mutant allele (Carroll et al., 2011;
Liu et al., 2008; Pfister et al., 2009).
Finally, our evidence has provided an initial demonstration that
transient suppression of huntingtin can be sufficient to amelio-
rate disease for an extended period of time. For diseases like
Huntington’s where a mutant protein product is tolerated for
decades prior to disease onset, this finding opens up the provoc-
ative possibility that transient suppression of huntingtin can lead
to a prolonged effect in patients. Indeed, this raises the prospect
that a transient decrease in huntingtin synthesis may allow for
clearance of disease causing species that form only very slowly
andmay then take weeks or months to reform. If so, then a single
transient application of ASOs may ‘‘reset the disease clock,’’
providing a benefit long after huntingtin suppression has ended.
Of obvious interest in this regard is to use the rodent examples to
determine how long the beneficial effect can persist after a single
ASO injection.EXPERIMENTAL PROCEDURES
Animals
BACHD animals were acquired from William Yang (Gray et al., 2008). BACHD
mice were maintained on the congenic FVB/N background, and only female
mice were used. YAC128 mice (Hodgson et al., 1999) were obtained from
the Genzyme colony at Charles River Laboratories and maintained on the
congenic FVB/NJ background. R6/2 animals (Mangiarini et al., 1996) were
obtained from Jackson laboratories and maintained by crossing transgene
positive males with F1 (CBA 3 C57BL6) females (CAG repeats wereNeuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc. 1041
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Transient ASO Therapy Produces Reversal of HDmaintained between 110 and 135). All procedures were accomplished using
a protocol approved by the Institutional Animal Care and Use Committee
(Department of Health and Human Services, NIH Publication 86–23). See
Supplemental Experimental Procedures for detailed surgical procedures.
Oligonucleotides
ASOs used in this study were 20 nucleotides in length with five 20-O-methox-
yethyl-modified nucleosides on the 50- and 30- termini and 10 oligodeoxynu-
cleotides in the central region to support RNase H. All of the internucleosidic
bonds were phosphorothioate to improve nuclease resistance and enhance
cellular uptake (Bennett and Swayze, 2010). Oligonucleotides were synthe-
sized as described previously (Cheruvallath et al., 2003; McKay et al., 1999).
ASOs were solubilized in 0.9% sterile saline solution or PBS. See Supple-
mental Experimental Procedures for ASO sequences.
Pathology and Immunostaining
Mice:Anesthetized animalswere subject to transcardial perfusionwith ice-cold
Sorenson’s phosphate buffer (SPB), and fixed with 4% paraformaldyhyde in
phosphate buffer. Brains were removed, and trimmed with coronal cuts imme-
diately rostral to the forebrain (removing the olfactory bulbs) and immediately
caudal to the cerebellum (removing the spinal cord). The remaining brain was
weighed in mg. Immunofluorescence was performed on 30 mm coronally cut
fixed frozen free-floating sections as described previously (Boille´e et al.,
2006).Monkey: Immunostainingwasperformed asdescribedpreviously (Smith
et al., 2006). SeeSupplemental Experimental Procedures for detailedmethods.
Quantitative Real-Time PCR (TaqMan)
RNA levels were measured by quantitative real-time RT-PCR method.
YAC128: total RNA was extracted using Ambion MagMAX-96 RNA isolation
kit (AppliedBiosystems). TheRNAwas reverse transcribed and amplified using
TaqMan One-Step RT-PCRMaster Mix Kit (Applied Biosystems). Quantitative
RT-PCR reactions were conducted and analyzed on an ABI PRISM 7500
Real-Time PCR System (Applied Biosystems). Expression levels for huntingtin
mRNA were normalized to Ppia (peptidylprolyl isomerase A) mRNA levels.
R6/2: cDNA is made from 1 mg of RNA (RNAeasy Mini Kit, QIAGEN) by reverse
transcription with random hexamers (SuperScript III, RT-PCR). Quantitative
real-time PCR was performed on the iQ cycler (Bio-Rad) using the TaqMan
system. Huntingtin mRNA levels were normalized to Atp5b and Eif4a2.
BACHD: qPCR was performed as previously described (Winer et al., 1999).
Total RNA was prepared from tissue lysate utilizing QIAGEN RNeasy 96
(QIAGEN). The prepared RNA was assayed for huntingtin and cyclophilin A
levels utilizing an ABI Prism 7700 (Applied Biosystems) and the resulting
data analyzed by ABI Sequence Detector v1.7a software. Monkey: huntingtin
mRNA levels were performed with the same protocol as the BACHD samples.
See Supplemental Experimental Procedures for primers sequences.
Immunoblotting
YAC128: Tissues were homogenized in T-Per lysis buffer (Pierce). Twenty to
thirty micrograms of total protein was resolved on a 3%–8% Novex tris-
acetate gel. Blots were probed with anti-Htt MAB2166 (1:2,000 Millipore)
and anti-b-tubulin (1:750, Santa Cruz Biotechnology). Proteins were visualized
by quantitative fluorescence (LI-COR Biosciences). Huntingtin protein levels
were normalized to b-tubulin and expressed as % vehicle treated controls.
BACHD: Tissues were homogenized in RIPA lysis buffer. Fifteen micrograms
of total protein lysate was resolved on a 4%–12% bis-tris gel (Invitrogen).
Proteins were transferred to a nitrocellulose membrane and probed with
MAB2166 and anti-GAPDH (1:5,000 Abcam).
Behavioral Analysis
All behavioral tests with the YAC128 mice were conducted independently at
Genzyme, and tests in BACHD and R6/2 animals were conducted indepen-
dently at UCSD. The range of numbers of animals used in the various behav-
ioral assays is listed in the figure legends. The exact animals numbers in each
treatment group, in each of the various behavioral assays is included in the
Supplemental Experimental Procedures. Also see Supplemental Experimental
Procedures for detailed procedures for accelerating rotarod, elevated-plus
maze, open-field test, light/dark analysis, body mass, and survival.1042 Neuron 74, 1031–1044, June 21, 2012 ª2012 Elsevier Inc.Statistics
Mean values were used for statistical analyses. Data are expressed as mean ±
SEM. For two groups, unpaired two-tailed t tests were used; for more than two
group comparisons, one-way ANOVAs were used followed by the post hoc
Tukey’s multiple comparison test; for more than two comparisons of two or
more groups, two-way ANOVAs followed by Bonferroni’s post hoc tests
were used (Prism GraphPad and Kalidagraph). p values for the ANOVAs are
reported in the figure legends, and p values from the post hoc tests are
included in the text when making paired comparisons. A chart listing the
post hoc comparisons of all rotarod analyses is provided (Figure S5). Signifi-
cance of survival was determined using the Kaplan-Meyer method. p < 0.05
was considered a statistically significant difference.
Please see Supplemental Experimental Procedures for the following
experimental procedures: Time resolved foerster resonance energy transfer
(TR-FRET) and capillary gel electrophoresis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.neuron.2012.05.009.
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